Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company focused on immunotherapy development that entered public markets in 2022 through a SPAC business combination, placing it within the healthcare and life sciences sector. On October 3, 2022, the company filed an 8-K current report with the SEC under accession number 0001575872-22-000912, disclosing a material corporate event consistent with its early post-merger operating period. The filing reflects Estrella's status as a newly listed entity navigating the transition from blank-check vehicle to an actively reporting public company in the competitive immunopharma space. Sign up for SpacDesk to access full filing history, sponsor details, and deal analytics for ESLA and hundreds of other SPAC transactions.